All posts

Follow Us

LinkedInInstagramX
Annual ResultsArchiveLast updated 17 November 20263 min read

KMS Medisurgi (KMSMEDI) Q4 FY26 Profit Nears Zero as Sales Slump and Costs Rise

The medical tape maker's profit margin collapsed to 0.2% in Q4 FY26 as new capacity costs hit before sales could recover.

By Abhinav Singhvi, Founder & CEO Hexawealth · Created 17 November 2026

KMS Medisurgi's Q4 FY26 saw profit plunge 97% year-on-year to just ₹0.01 crore. Revenue fell nearly 9%, while a new coating line doubled depreciation, squeezing margins to near break-even.

For KMS Medisurgi, a small medical tape maker, the promise of new capacity has collided with the reality of falling sales. The March quarter capped a difficult year where profit nearly vanished, dropping 97% from a year ago to just ₹0.01 crore.

Revenue fell 8.7% year-on-year to ₹5.59 crore, while net profit margin collapsed to 0.2% from 5.9%. The full year was no better, with sales down 12.4% and profit falling 43.2%.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ4 FY24 6.73, Q2 FY25 7.81, Q4 FY25 6.12, Q2 FY26 6.62, Q4 FY26 5.59. Q4 FY24 -0.15, Q2 FY25 0.08, Q4 FY25 0.36, Q2 FY26 0.23, Q4 FY26 0.01-20-1001020Q4 '24Q2 '25Q4 '25Q2 '26Q4 '26
  • Revenue (₹ Cr), Q4 FY24: 6.73
  • Revenue (₹ Cr), Q2 FY25: 7.81
  • Revenue (₹ Cr), Q4 FY25: 6.12
  • Revenue (₹ Cr), Q2 FY26: 6.62
  • Revenue (₹ Cr), Q4 FY26: 5.59
  • Profit (₹ Cr), Q4 FY24: -0.15
  • Profit (₹ Cr), Q2 FY25: 0.08
  • Profit (₹ Cr), Q4 FY25: 0.36
  • Profit (₹ Cr), Q2 FY26: 0.23
  • Profit (₹ Cr), Q4 FY26: 0.01

Revenue (₹ Cr)

Revenue (₹ Cr)Q4 FY24 6.73, Q2 FY25 7.81, Q4 FY25 6.12, Q2 FY26 6.62, Q4 FY26 5.5905101520Q4 '24Q2 '25Q4 '25Q2 '26Q4 '26
  • Revenue (₹ Cr), Q4 FY24: 6.73
  • Revenue (₹ Cr), Q2 FY25: 7.81
  • Revenue (₹ Cr), Q4 FY25: 6.12
  • Revenue (₹ Cr), Q2 FY26: 6.62
  • Revenue (₹ Cr), Q4 FY26: 5.59

Profit (₹ Cr)

Profit (₹ Cr)Q4 FY24 -0.15, Q2 FY25 0.08, Q4 FY25 0.36, Q2 FY26 0.23, Q4 FY26 0.01-2-1012Q4 '24Q2 '25Q4 '25Q2 '26Q4 '26
  • Profit (₹ Cr), Q4 FY24: -0.15
  • Profit (₹ Cr), Q2 FY25: 0.08
  • Profit (₹ Cr), Q4 FY25: 0.36
  • Profit (₹ Cr), Q2 FY26: 0.23
  • Profit (₹ Cr), Q4 FY26: 0.01

Net Profit Margin

Net Profit MarginQ4 FY24 -2.2%, Q2 FY25 1.0%, Q4 FY25 5.9%, Q2 FY26 3.5%, Q4 FY26 0.2%-8%-4%0%4%8%Q4 '24Q2 '25Q4 '25Q2 '26Q4 '26
  • Net Profit Margin, Q4 FY24: -2.2%
  • Net Profit Margin, Q2 FY25: 1.0%
  • Net Profit Margin, Q4 FY25: 5.9%
  • Net Profit Margin, Q2 FY26: 3.5%
  • Net Profit Margin, Q4 FY26: 0.2%
MetricCurrentQ4 FY26Same quarter LYQ4 FY25
Revenue (₹ Cr)
5.59YoY -8.7%
6.12
Profit (₹ Cr)
0.01YoY -97%
0.36
Net Profit Margin
0.2%YoY -97%
5.9%

Why the new line dragged profit down

A new coating line, added during FY26 to nearly double capacity, is the main culprit. According to a report from Newboard, this investment added depreciation before it added sales. Depreciation expense surged 100% year-on-year and 47% sequentially, directly eroding the bottom line.

Raw material costs, which make up most expenses, did fall with sales. But the fixed cost of the new machinery could not be avoided, creating a severe operating leverage problem in a quarter of declining revenue.

The challenge of a single customer

Compounding the operational squeeze is a concentrated customer base. Newboard notes that about 63% of FY26 revenue came from sales to KMS Manufacturing Co., a firm owned by a company director. This reliance on one related-party buyer makes judging genuine market demand difficult and leaves revenue vulnerable to the timing and pricing decisions within the group.

Live Chart

· KMSMEDI

(BSE)

ISIN: INE870V01014

The company has announced plans to make adhesive tapes for automotive and electrical uses on the same new machines. However, no launch timeline or specific customers have been named, leaving the plan speculative for now.

What comes next?

The outlook for the current year, FY27, appears weak. Data from mCapital.in shows unaudited H1 FY27 revenue of ₹6.17 crore, down 6.7% from the year-ago period. Profit before tax was a mere ₹0.034 crore.

Based on this, mCapital estimates FY27 revenue could fall 2.5% to 7.4%, with net profit potentially dropping 72% to 88%. The auditor also flagged qualifications on stock reconciliation and employee benefits, adding to the concerns.

Key Points

  • Profit collapsed to near break-even in Q4 FY26, with a net margin of just 0.2%.
  • A major capacity addition doubled depreciation costs before generating new sales, severely pressuring margins.
  • Most revenue comes from a single related-party buyer, obscuring true market demand.
  • Early FY27 figures point to continued revenue decline and severely depressed profitability.

Hexa Perspective

The quarter reveals a company caught in a transition it cannot yet fund. KMS Medisurgi invested for growth, but the sales to fill that new capacity have not materialized, and its dependence on one buyer offers little visibility on when they might.

The path forward hinges entirely on commercializing its planned diversification into industrial tapes. Until that plan gains concrete customers and orders, the high fixed costs from the new line will keep profitability under severe pressure, making a recovery in earnings distant.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

KMS Medisurgi (KMSMEDI) Q4 FY26 results, revenue and profits.

Frequently asked questions

What were KMS Medisurgi's Q4 FY26 results?
KMS Medisurgi reported a Q4 FY26 profit of ₹0.01 crore, a 97% drop from the ₹0.36 crore profit a year ago. Revenue for the quarter was ₹5.59 crore, down 8.7% year-on-year. The net profit margin collapsed to 0.2% from 5.9% in Q4 FY25.
Why did KMS Medisurgi's Q4 FY26 profit drop 97%?
KMS Medisurgi's profit plunged due to a double squeeze. Revenue fell 8.7% year-on-year, while depreciation expense doubled due to a new coating line. This fixed cost hit came before the new capacity could generate additional sales, collapsing the net profit margin to 0.2%.
What was KMS Medisurgi's net profit margin in Q4 FY26?
KMS Medisurgi's net profit margin was 0.2% in Q4 FY26, a sharp drop of 570 basis points from the 5.9% margin in the same quarter last year. The margin compression was driven by higher depreciation costs on new machinery amid declining sales.
What caused the 100% increase in KMS Medisurgi's depreciation in Q4 FY26?
Depreciation expense surged 100% year-on-year in Q4 FY26 due to the commissioning of a new coating line. A Newboard report states this line was added during FY26, nearly doubling capacity, and began charging depreciation before it contributed meaningfully to sales growth.
What is the revenue outlook for KMS Medisurgi in FY27?
The outlook for FY27 revenue is weak. Based on unaudited H1 FY27 figures, mCapital.in estimates full-year revenue could decline between 2.5% and 7.4% from the FY26 level of ₹12.21 crore. This implies revenue in the range of ₹11.3 to ₹11.9 crore.
What is KMS Medisurgi's plan for its new coating capacity?
KMS Medisurgi plans to use its new coating line to produce adhesive tapes for automotive and electrical applications, diversifying beyond medical tapes. However, as noted by Newboard, the plan currently lacks a defined launch timeline or named customers.
Who are KMS Medisurgi's main customers?
A significant portion of KMS Medisurgi's sales go to a single related party. According to Newboard, about 63% of FY26 revenue, or ₹7.7 crore, came from sales to KMS Manufacturing Co., a proprietorship owned by a company director.
What was KMS Medisurgi's FY26 annual profit?
KMS Medisurgi's annual profit for FY26 was ₹0.25 crore, a decline of 43.2% from the ₹0.44 crore profit in FY25. Annual revenue for FY26 was ₹12.21 crore, down 12.4% from the previous year.
KMS Medisurgi Q4 FY26 results
KMS Medisurgi's Q4 FY26 results, announced in May 2026, showed revenue of ₹5.59 crore and a net profit of ₹0.01 crore. This represented an 8.7% drop in revenue and a 97.2% plunge in profit compared to the March 2025 quarter.
KMS Medisurgi share price results
KMS Medisurgi's share price was ₹132.80 on the day its Q4 FY26 results were filed in May 2026, according to lax.sh data. The stock price reaction to the weak quarterly results, which showed a 97% profit drop, is not detailed in the available research.